Immunome (NASDAQ:IMNM) Given “Outperform” Rating at Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a research report issued on Monday,RTT News reports. They presently have a $33.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 228.69% from the stock’s previous close.

IMNM has been the subject of a number of other reports. Piper Sandler dropped their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Stephens began coverage on shares of Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $28.83.

Immunome Stock Down 5.3 %

Shares of Immunome stock traded down $0.56 during trading on Monday, reaching $10.04. 1,035,892 shares of the stock were exchanged, compared to its average volume of 637,222. The stock’s fifty day moving average is $11.77 and its 200 day moving average is $12.99. The firm has a market cap of $626.67 million, a price-to-earnings ratio of -1.24 and a beta of 1.90. Immunome has a 1 year low of $8.97 and a 1 year high of $30.96.

Insiders Place Their Bets

In other Immunome news, insider Robert Lechleider bought 15,805 shares of the stock in a transaction dated Thursday, November 21st. The stock was purchased at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the acquisition, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Philip Tsai bought 21,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the acquisition, the chief technology officer now directly owns 21,000 shares of the company’s stock, valued at approximately $198,030. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders purchased 102,862 shares of company stock worth $978,045 over the last three months. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several large investors have recently made changes to their positions in IMNM. Bank of New York Mellon Corp purchased a new position in shares of Immunome during the second quarter valued at approximately $1,816,000. Rhumbline Advisers bought a new stake in shares of Immunome during the second quarter valued at approximately $813,000. Victory Capital Management Inc. increased its position in shares of Immunome by 39.0% during the second quarter. Victory Capital Management Inc. now owns 493,288 shares of the company’s stock valued at $5,969,000 after acquiring an additional 138,526 shares in the last quarter. Arizona State Retirement System increased its position in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after acquiring an additional 918 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Immunome during the second quarter valued at approximately $81,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.